Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

MYGN Myriad Genetics Inc

Price (delayed)

$5.18

Market cap

$477.48M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.12

Enterprise value

$543.28M

Myriad Genetics Inc., is a leading genetic testing and precision medicine company dedicated to transforming patient lives worldwide. Myriad discovers and commercializes genetic tests that: determine the risk of developing ...

Highlights
The EPS has soared by 60% YoY and by 21% from the previous quarter
The company's net income has surged by 57% YoY and by 20% QoQ
The quick ratio has declined by 8% year-on-year but it has increased by 2.9% since the previous quarter
The debt has grown by 12% from the previous quarter and by 7% YoY
The company's equity fell by 7% YoY

Key stats

What are the main financial stats of MYGN
Market
Shares outstanding
92.18M
Market cap
$477.48M
Enterprise value
$543.28M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.67
Price to sales (P/S)
0.57
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.65
Earnings
Revenue
$831.3M
Gross profit
$582M
Operating income
-$124.5M
Net income
-$101.4M
EBIT
-$123.8M
EBITDA
-$53.9M
Free cash flow
-$35.8M
Per share
EPS
-$1.12
EPS diluted
-$1.12
Free cash flow per share
-$0.39
Book value per share
$7.72
Revenue per share
$9.1
TBVPS
$5.06
Balance sheet
Total assets
$1.01B
Total liabilities
$301.2M
Debt
$157.6M
Equity
$704.9M
Working capital
$136.1M
Liquidity
Debt to equity
0.22
Current ratio
1.9
Quick ratio
1.4
Net debt/EBITDA
-1.22
Margins
EBITDA margin
-6.5%
Gross margin
70%
Net margin
-12.2%
Operating margin
-15%
Efficiency
Return on assets
-9.7%
Return on equity
-14.1%
Return on invested capital
-33.4%
Return on capital employed
-14.5%
Return on sales
-14.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MYGN stock price

How has the Myriad Genetics stock price performed over time
Intraday
-0.96%
1 week
-2.08%
1 month
33.16%
1 year
-76.95%
YTD
-62.22%
QTD
-41.6%

Financial performance

How have Myriad Genetics's revenue and profit performed over time
Revenue
$831.3M
Gross profit
$582M
Operating income
-$124.5M
Net income
-$101.4M
Gross margin
70%
Net margin
-12.2%

MYGN financials

The net margin has soared by 60% YoY and by 20% from the previous quarter
The company's net income has surged by 57% YoY and by 20% QoQ
The company's operating margin has surged by 50% YoY but it fell by 2% QoQ
The operating income rose by 47% YoY

Price vs fundamentals

How does MYGN's price correlate with its fundamentals

MYGN Price vs fundamentals

MYGN Earnings waterfall

MYGN Price vs fair value

Growth

What is Myriad Genetics's growth rate over time

MYGN growth chart

Valuation

What is Myriad Genetics stock price valuation
P/E
N/A
P/B
0.67
P/S
0.57
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.65

Valuation vs average

Price to earnings (P/E)

The EPS has soared by 60% YoY and by 21% from the previous quarter

Price to book (P/B)

MYGN's price to book (P/B) is 71% lower than its last 4 quarters average of 2.3 and 68% lower than its 5-year quarterly average of 2.1
The company's equity fell by 7% YoY

Price to sales (P/S)

The P/S is 77% lower than the 5-year quarterly average of 2.5 and 73% lower than the last 4 quarters average of 2.1
Myriad Genetics's revenue has increased by 7% YoY

Efficiency

How efficient is Myriad Genetics business performance
MYGN's return on equity has surged by 56% year-on-year and by 19% since the previous quarter
Myriad Genetics's return on assets has surged by 52% YoY and by 18% QoQ
The ROS has soared by 50% YoY but it has contracted by 3.5% from the previous quarter
The return on invested capital has grown by 42% year-on-year but it has declined by 3.1% since the previous quarter

Dividends

What is MYGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MYGN.

Financial health

How did Myriad Genetics financials performed over time

Assets vs liabilities

The company's total liabilities fell by 14% YoY and by 8% QoQ
Myriad Genetics's total assets has decreased by 9% YoY and by 2.1% from the previous quarter

Debt vs equity

The debt is 78% less than the equity
The debt to equity is up by 16% year-on-year and by 10% since the previous quarter
The debt has grown by 12% from the previous quarter and by 7% YoY

Balance sheet

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.